ASTC

Astrotech is, by its own admission, a development-stage company: the 10-K states its business units 'have earned limited revenues and it is uncertain whether they will earn any revenues in the future or whether any of them will ultimately be profitable,' and that it 'may need to raise additional capital.' The numbers confirm it. FY2025 revenue was just $1.00M, down 41.2% year over year, and the five-year history shows no durable trend — $334K → $869K → $750K → $1.70M → $1.00M — this is lumpy, order-by-order revenue (a single $429K TRACER 1000 purchase order and a handful of units in 16 countries), not a scaling business. Against that, the net loss widened to -$13.8M and operating cash flow was -$13.0M, funded almost entirely by R&D ($8.14M) on the AMS/GC platform and the BreathTest-1000. Operating margin of -1473% and a -$251M accumulated deficit tell you this company has consumed a quarter-billion dollars without reaching commercial viability.

Valuation makes the setup worse, not better. At $10.45 the market cap is $18.4M on $1.00M of revenue — an 18.4x price-to-sales multiple for a shrinking, deeply unprofitable top line. There is no P/E (losses), and no growth to grow into the multiple. The one genuine positive is the balance sheet: liabilities are only $4.89M against $22.1M of equity (0.22x), with $22.0M of current assets versus $2.45M of current liabilities and no long-term debt. Book value is roughly $12.56/share, so the stock trades below book — but that cushion is deceptive because the company is burning ~$13M a year, so at the current run-rate the equity is depleted in under two years absent a capital raise, which management flags as likely and which would dilute the tiny 1.76M-share float.